natgillin/translations-raw huggingface dataset:
Three measuring spoons of different measures are provided. 
Priložene so tri merilne žličke različnih mer.
If this occurs, please discuss it with your doctor, because the absence of your period may be caused by pregnancy (see Pregnancy and breast-feeding section above). 
Če se to zgodi, se posvetujete s svojim zdravnikom, ker lahko izostanek menstruacije pomeni, da ste noseči (glejte poglavje Nosečnost in dojenje zgoraj).
The tablets should be taken with a large volume of water. 
Zdravilo je treba jemati z veliko količino vode.
Your doctor will tell you the amount of granules you should take. 
Zdravnik vam bo povedal količino zrnc, ki jih morate vzeti.
Do not use this medicine after the expiry date which is stated on the carton and the bottle label after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki na plastenki poleg oznake “EXP”.
Patients with these rare disorders have a deficiency of certain liver enzymes and are therefore unable to eliminate nitrogen waste. 
Bolniki s temi redkimi motnjami imajo premalo določenih encimov v jetrih in zato ne morejo odstranjevati odpadnega dušika.
You will need regular blood tests to determine the correct daily dose. 
Opravljati boste morali redne krvne preiskave, da se bo določil pravilni dnevni odmerek zdravila AMMONAPS.
These medicines may change the effect of AMMONAPS and you will need more frequent blood controls. 
Ta zdravila lahko spremenijo delovanje zdravila AMMONAPS in boste morali pogosteje na preiskave krvi.
- if you are pregnant. 
- če ste noseči, - če dojite,
The volume of distribution of phenylbutyrate is 0.2 l/kg. 
Volumen porazdelitve fenilbutirata je 0,2 l/kg.
Evaluation of experimental animal studies has shown reproductive toxicity, i.e. effects on the development of the embryo or the foetus. 
Študije na živalih so pokazale reproduktivno toksičnost, tj. učinkovanje na razvoj zarodka ali ploda.
The safety of this medicinal product for use in human pregnancy has not been established. 
Varnost tega zdravila med nosečnostjo še ni ugotovljena.
Common: Syncope, headache 
Pogosti: sinkopa, glavobol
If you are sexually active and your period stops altogether, do not assume that this is caused by AMMONAPS. 
Če ste spolno dejavni in vam menstruacija izostane, ne domnevajte, da gre za učinke zdravila AMMONAPS.
Nitrogen waste, in the form of ammonia, is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma. 
Odpadni dušik v obliki amonijaka je še posebej toksičen za možgane in v hudih primerih povzroči zmanjšano zavest in komo.
What AMMONAPS is and what it is used for 
Kaj je zdravilo AMMONAPS in za kaj ga uporabljamo
The safety and efficacy of doses in excess of 20 g/day have not been established. 
Varnost in učinkovitost odmerkov večjih od 20 g/dan še ni bila dokazana.
When the granules are dissolved in water you get a milky white liquid. 
Ko se zrnca raztopijo v vodi, nastane mlečno bela tekočina.
If you require laboratory tests, it is important to remind your doctor that you are taking AMMONAPS, since sodium phenylbutyrate may influence certain laboratory test results. 
Če boste morali opraviti laboratorijske preiskave, je pomembno, da opomnite svojega zdravnika, da jemljete zdravilo AMMONAPS, ker lahko natrijev fenilbutirat vpliva na rezultate nekaterih laboratorijskih preiskav.
Plasma glutamine should be maintained at levels less than 1,000 µmol/l. 
Plazemske koncentracije glutamina se morajo vzdrževati pod 1.000 µmol/l.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
One case of overdose occurred in a 5-month old infant with an accidental single dose of 10 g (1370 mg/kg). 
Do prevelikega odmerjanja je prišlo pri petmesečnem dojenčku z naključnim zaužitjem enkratnega odmerka 10 g (1370 mg/kg).
What AMMONAPS is and what it is used for What you need to know before you take AMMONAPS How to take AMMONAPS 
Kaj je zdravilo AMMONAPS in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo AMMONAPS Kako jemati zdravilo AMMONAPS
The adverse reactions are listed below, by system organ class and by frequency. 
Neželeni učinki so navedeni spodaj, razvrščeni po organskih sistemih in po pogostnosti.
If you forget to take AMMONAPS 
Če ste pozabili vzeti zdravilo AMMONAPS
Other medicines and AMMONAPS 
Druga zdravila in zdravilo AMMONAPS
250 tablets 500 tablets 
250 tablet 500 tablet
In the event of an overdose, discontinue the treatment and institute supportive measures. 
V primeru prevelikega odmerjanja je potrebno nemudoma prekiniti z zdravljenjem in izvesti podporne ukrepe.
Frequency is defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Pogostnost neželenih učinkov je opredeljena kot zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki
In clinical trials with AMMONAPS, 56 % of the patients experienced at least one adverse event and 78 % of these adverse events were considered as not related to AMMONAPS. 
4.8 Neželeni učinki V kliničnih preskušanjih z zdravilom AMMONAPS je 56 % bolnikov doživelo najmanj en neželeni dogodek, vendar se za 78 % teh neželenih dogodkov smatra, da niso povezani z zdravilom AMMONAPS.
Approximately 80 - 100 % of the medicinal product is excreted by the kidneys within 24 hours as the conjugated product, phenylacetylglutamine. 
Približno 80 -100 % zdravila se izloči preko ledvic v 24 urah v obliki konjugiranega produkta, fenilacetilglutamina.
• 9.9 - 13.0 g/m2/day in children weighing more than 20 kg, adolescents and adults. 
• 9,9 - 13,0 g/m2/dan pri otrocih, ki tehtajo več kot 20 kg, ter pri mladostnikih in pri odraslih.
The safety and efficacy of doses in excess of 20 g/day (40 tablets) have not been established. 
Varnost in učinkovitost odmerkov večjih od 20 g/dan (40 tablet), še ni bila dokazana.
What you need to know before you take AMMONAPS Do not take AMMONAPS 
Kaj morate vedeti, preden boste vzeli zdravilo AMMONAPS Ne jemljite zdravila AMMONAPS
To be taken into consideration by patients on a sodium controlled diet. 
To morajo upoštevati bolniki, ki so na dieti z nadzorovanim vnosom natrija.
• The granules left in the spoon are one spoonful 
• Zrnca, ki ostanejo v žlički so ena merica.
AMMONAPS may be required life-long unless orthotopic liver transplantation is elected. 
Zdravljenje z zdravilom AMMONAPS je lahko potrebno celo življenje, če ne pride do odločitve za ortotopično presaditev jeter.
Three spoons (one small white spoon, one medium sized yellow spoon and one large blue spoon) are included to measure your daily dose. 
Priložene so tri merilne žličke (ena majhna bela žlička, ena srednja rumena žlička in ena velika modra žlička), s katerimi odmerite svoj dnevni odmerek.
The daily dose should be individually adjusted according to the patient's protein tolerance and the daily dietary protein intake needed to promote growth and development. 
Dnevni odmerek se mora prilagoditi individualno glede na bolnikovo toleranco za beljakovine in na potreben dnevni vnos beljakovin za pospeševanje rasti in razvoja.
You should take AMMONAPS with each meal or feeding. 
Zdravilo AMMONAPS morate vzeti pri vsakem obroku ali hranjenju.
Please note that the reconstituted granules will normally produce a milky white suspension. 
Pri suspendiranju zrnc običajno nastane mlečna bela suspenzija.
Cerebral synapse maturation was retarded and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth. 
Opazili so tudi zakasnjeno zorenje cerebralnih sinaps in zmanjšano število delujočih živčnih končičev v možganih ter posledično zmanjšano rast možganov.
Ammonaps 500 mg [outer packaging only] 
Ammonaps 500 mg [samo zunanja ovojnina]
Where AMMONAPS granules need to be added to food, liquid or water, it is important that it is taken immediately after mixing. 
Pri bolnikih, kjer se zdravilo AMMONAPS dodaja hrani, tekočinam ali vodi, je pomembno, da se zdravilo vzame takoj po vmešanju.
Each bottle contains 250 or 500 tablets. 
Vsaka plastenka vsebuje 250 ali 500 tablet.
AMMONAPS is not recommended for the management of acute hyperammonaemia, which is a medical emergency. 
Zdravila AMMONAPS ne priporočajo za zdravljenje akutne hiperamonemije, ki je medicinski nujen primer.
Reversal of pre-existing neurologic impairment is not likely to occur with treatment, and neurologic deterioration may continue in some patients. 
Z zdravljenjem ni verjetno, da bi prišlo do izboljšanja obstoječih nevroloških motenj, pri nekaterih bolnikih se lahko tudi nadaljuje slabšanje nevroloških stanj.
Manifestations of neurotoxicity were predominantly somnolence, fatigue and light-headedness. 
Znaki nevrotoksičnosti so bili predvsem somnolenca, utrujenost, omotičnost.
There have been published reports of hyperammonaemia being induced by haloperidol and by valproate. 
Objavljena so poročila o hiperamonemiji inducirani s haloperidolom in z valproatom.
AMMONAPS treatment should be supervised by a physician experienced in the treatment of urea cycle disorders. 
Zdravljenje z zdravilom AMMONAPS naj nadzoruje zdravnik, ki je izkušen pri zdravljenju motenj ciklusa sečnine.
If persistent vomiting occurs, you should contact your doctor immediately. 
Če začnete vztrajno bruhati, nemudoma obvestite svojega zdravnika.
It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. 
Indicirano je tudi pri bolnikih, pri katerih se bolezen pojavi s t.i. zakasnjenim pojavom (delne pomanjkljivosti encimov, ki se pokažejo po prvem mesecu življenja) in imajo anamnezo hiperamonemične encefalopatije.
Their cognitive performance remained relatively stable during phenylbutyrate therapy. 
Njihove kognitivne sposobnosti pa so med zdravljenjem z fenilbutiratom ostajale relativno stabilne.
AMMONAPS helps the body to eliminate nitrogen waste, reducing the amount of ammonia in your body. 
Zdravilo AMMONAPS telesu pomaga odstraniti odpadni dušik in v njem zmanjšati količino amonijaka.
The majority of the patients who were tested had an IQ in the average to low average/borderline mentally retarded range. 
Vrednosti IQ večine bolnikov, ki so bili testirani, so bile v območju povprečja do območja nizkega povprečja oz. mejne umske zaostalosti.
The granules are off-white. 
Zrnca so sivo bela.
You will need to have treatment and to follow a diet throughout your life, unless you have a successful liver transplantation. 
Zdravljenje in posebno prehrano boste potrebovali celo življenje, če vam ne bodo uspešno presadili jeter.
With haemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in new-borns diagnosed after birth (but within the first month of life) increased to almost 80 % with most deaths occurring during an episode of acute hyperammonaemic encephalopathy. 
S hemodializo, uporabo alternativnih poti izločanja odpadnega dušika (natrijev fenilbutirat, natrijev benzoat in natrijev fenilacetat), omejevanjem prehranskega vnosa beljakovin in (v določenih primerih) dopolnili esencialnih aminokislin se je stopnja preživetja pri novorojenčkih s postavitvijo diagnoze v prvem mesecu življenja povečala na skoraj 80 %; pri čemer do večine smrti pride med epizodo hiperamoniemične encefalopatije.
- if you have decreased kidney or liver function, since AMMONAPS is eliminated from the body through the kidney and liver. 
- če imate zmanjšano delovanje ledvic ali jeter, ker se zdravilo AMMONAPS odstranjuje iz telesa preko ledvic in jeter.
When high doses of phenylacetate (190 - 474 mg/kg) were given subcutaneously to rat pups, decreased proliferation and increased loss of neurons were observed, as well as a reduction in CNS myelin. 
Pri dajanju visokih odmerkov fenilacetata (190 - 474 mg/kg) podganjim mladičem podkožno, so opazili zmanjšano proliferacijo nevronov in pospešeno izgubo le-teh. Skrčil se je tudi mielin v CŽS.
Therapeutic monitoring: Plasma levels of ammonia, arginine, essential amino acids (especially branched chain amino acids), carnitine and serum proteins should be maintained within normal limits. 
Nadzorovanje zdravljenja: Plazemske koncentracije amoniaka, arginina, esencialnih aminokislin (predvsem razvejane verige aminokislin), karnitina in serumskih beljakovin se morajo vzdrževati v normalnih mejah.
- if you suffer from heart failure, a decrease in your kidney function or other diseases, where the retention of the sodium salt contained in this medicine, may make your condition worse. 
- če vam odpoveduje srce, če imate zmanjšano delovanje ledvic ali druge bolezni, kjer lahko zadrževanje natrijeve soli, ki jo vsebuje to zdravilo, poslabša vaše stanje.
It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). 
Zdravilo AMMONAPS je indicirano pri vseh bolnikih, pri katerih se bolezen pojavi s t.i. neonatalnim pojavom (celotne pomanjkljivosti encimov, ki se pokažejo v prvih 28 dneh življenja).
It has not been determined if phenylacetate is secreted in human milk and therefore the use of AMMONAPS is contra-indicated during lactation (see section 4.3). 
Ni znano ali fenilacetat prehaja v materino mleko, zato je uporaba zdravila AMMONAPS med dojenjem kontraindicirana (glejte poglavje 4.3).
The total daily dose of AMMONAPS should be divided into equal amounts and given with each meal (e.g. three times per day). 
Celokupni dnevni odmerek zdravila AMMONAPS naj se razdeli na enake dele in se daje z vsakim obrokom (npr. trikrat dnevno).
In patients with impaired hepatic function the conversion of phenylacetate to phenylacetylglutamine may be relatively slower. 
Pri bolnikih z motnjami v delovanju jeter je lahko pretvorba fenilacetata v fenilacetilglutamin relativno počasnejša.
AMMONAPS does not completely prevent the occurrence of an acute excess of ammonia in the blood and is not appropriate for treating such a condition, which is a medical emergency. 
Zdravilo AMMONAPS ne prepreči pojava odvečnih količin amonija v krvi popolnoma in ni primeren za zdravljenje takšnega stanja, ki je medicinski nujen primer.
The daily dose of AMMONAPS will be calculated from your protein tolerance, diet and body weight or body surface. 
Dnevni odmerek zdravila AMMONAPS se bo določil na podlagi vaše tolerance za beljakovine, prehrane in telesne mase ali površine.
Arginine supplementation is required for patients diagnosed with deficiency of argininosuccinate synthetase at a dose of 0.4 - 0.7 g/kg/day or 8.8 - 15.4 g/m2/day. 
Dopolnjevanje prehrane z argininom je potrebno za bolnike z diagnozo pomanjkljivosti argininosukcinat-sintaze, in sicer z odmerki 0,4 - 0,7 g/kg/dan ali 8,8 - 15,4 g/m2/dan.
HDPE bottles, with child resistant caps, containing 250 or 500 tablets. 
Plastenke iz HDPE z za otroke varno zaporko, ki vsebujejo 250 ali 500 tablet.
A probable case of toxic reaction to AMMONAPS (450 mg/kg/d) was reported in an 18-year old anorectic female patient who developed a metabolic encephalopathy associated with lactic acidosis, severe hypokalaemia, pancytopaenia, peripheral neuropathy, and pancreatitis. 
Poročali so o verjetnem primeru toksične reakcije na zdravilo AMMONAPS (450 mg/kg/d) pri 18-letni anorektični bolnici, pri kateri se je razvila metabolična encefalopatija, povezana z laktično acidozo, težko hipokaliemijo, pancitopenijo, periferno nevropatijo in pankreatitisom.
In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recovered from hyperammonaemic encephalopathy and were then treated chronically with dietary protein restriction and sodium phenylbutyrate, the survival rate was 98 %. 
Pri bolnikih z zakasnjenim pojavom bolezni (vključno z ženskami, heterozigotnimi za pomanjkljivost ornitin transkarbamoilaze), ki so si opomogli od hiperamoniemične encefalopatije in so bili kasneje kronično zdravljeni z omejevanjem prehranskega vnosa beljakovin ter natrijevim fenilbutiratom, je bila stopnja preživetja 98 %.
Mix the granules with water until there are no dry granules left (stirring the solution helps to dissolve the granules). 
Zmešajte zrnca z vodo, dokler se ne raztopijo (če raztopino premešate, se zrnca hitreje raztopijo).
The patient developed diarrhoea, irritability and metabolic acidosis with hypokalaemia. 
Bolnik je dobil diarejo, postal razdražljiv in je razvil metabolično acidozo s hipokaliemijo.
The use of AMMONAPS tablets is indicated for adults and children who are able to swallow tablets. 
Jemanje zdravila AMMONAPS je indicirano pri odraslih in otrocih, ki lahko požirajo tablete.
Even on therapy, acute hyperammonaemic encephalopathy may occur in a number of patients. 
Pri kar številnih bolnikih se lahko akutna hiperamonemična encefalopatija pojavi celo med zdravljenjem.
Patients with a gastrostomy or nasogastric tube 
Bolniki z gastrostomo ali nazogastrično cevko
Do not use AMMONAPS if you are breast-feeding, because this medicine can pass into the breastmilk and harm your baby. 
Ne jemljite zdravila AMMONAPS, če dojite, ker lahko prehaja v mleko in škoduje vašemu otroku.
Previously, neonatal-onset presentation of urea cycle disorders was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogenfree analogues. 
Včasih so bile motnje ciklusa sečnine z neonatalnim pojavom skoraj brez izjeme smrtne v prvem letu življenja - navkljub zdravljenju s peritonealno dializo in esencialnimi aminokislinami ali njihovimi analogi brez dušika.
AMMONAPS tablets should not be given to children who are not able to swallow tablets. 
Zdravila AMMONAPS tablete ne smete dajati otrokom, ki tablet ne morejo pogoltniti.
HDPE bottles, with child resistant caps, containing 266 g or 532 g of granules. 
Plastenke iz HDPE z za otroke varno zaporko, ki vsebujejo 266 g ali 532 g zrnc.
Results indicate that sodium phenylbutyrate did not induce any mutagenic effects in the Ames test with or without metabolic activation. 
Rezultati kažejo, da natrijev fenilbutirat ni induciral mutagenih učinkov v Amesovem preskusu niti s presnovno aktivacijo niti brez te aktivacije.
Less frequent manifestations were confusion, headache, dysgeusia, hypacusis, disorientation, impaired memory and exacerbation of a pre-existing neuropathy. 
Manj pogosti znaki nevrotoksičnosti pa so bili zmedenost, glavobol, disgeusija, hipakuza, dezorientacija, poslabšanje spomina in poslabšanje že obstoječih nevropatij.
If you take more AMMONAPS than you should 
Če ste vzeli večji odmerek zdravila AMMONAPS, kot bi smeli
The disposition of phenylbutyrate and its metabolites has also been studied in cancer patients following intravenous infusion of sodium phenylbutyrate (up to 2 g/m²) or phenylacetate. 
Razporejanje fenilbutirata in njegovih presnovkov je bilo preučeno tudi pri bolnikih z rakom po intravenski infuziji natrijevega fenilbutirata (do 2 g/m2) ali fenilacetata.
• Use the correct spoon to dispense the following amount of Ammonaps: 1.2 g = small white spoon, 3.3 g = medium sized yellow spoon and 9.7 g = large blue spoon 
• Izberite pravilno merilno žličko za odmerjanje naslednje količine zdravila Ammonaps: 1,2 g = majhna bela žlička; 3,3 g = srednja rumena žlička in 9,7 g = velika modra žlička.
- when given to small children, since they may not be able to swallow the tablets and may choke. 
- kadar se z zdravilom AMMONAPS zdravijo majhni otroci, ker morda ne morejo pogoltniti tablet in se lahko zadušijo.
Mix the measured dose with solid foods (such as mashed potatoes or apple sauce) or liquid foods (such as water, apple juice, orange juice or protein-free infant formulas) and take it immediately after mixing. 
Zmešajte odmerek s čvrsto hrano (na primer krompirjevim pirejem ali jabolčno čežano) ali tekočo hrano (na primer z vodo, jabolčnim sokom, pomarančnim sokom ali brezbeljakovinskimi formulami za dojenčke in takoj po vmešanju zaužijte.
In normal volunteers gender differences were found in the pharmacokinetic parameters of phenylbutyrate and phenylacetate (AUC and Cmax about 30 - 50 % greater in females), but not phenylacetylglutamine. 
Pri normalnih prostovoljcih so bile med spoloma opažene razlike v farmakokinetičnih parametrih fenilbutirata in fenilacetata (vrednosti AUC in Cmax sta bili približno 30 - 50 % višji pri ženskah), vendar razlik ni bilo opaziti pri parametrih fenilacetilglutamina.
These symptoms are consistent with the accumulation of phenylacetate, which showed dose-limiting neurotoxicity when administered intravenously at doses up to 400 mg/kg/day. 
Ti simptomi so skladni z nakopičenjem fenilacetata, za katerega je bila dokazana nevtrotoksičnost odvisna od intravenskega odmerka pri odmerkih 400 mg/kg/dan.
Based on studies of phenylacetylglutamine excretion in patients with urea cycle disorders it is possible to estimate that, for each gram of sodium phenylbutyrate administered, between 0.12 and 0.15 g of phenylacetylglutamine nitrogen are produced. 
Na podlagi študij izločanja fenilacetilglutamina pri bolnikih z motnjami ciklusa sečnine, lahko ocenimo, da se na vsak odmerjen gram natrijevega fenilbutirata proizvede med 0,12 in 0,15 g dušika v obliki fenilacetilglutamina.
Plasma and urine concentrations of phenylbutyrate and its metabolites have been obtained from fasting normal adults who received a single dose of 5 g of sodium phenylbutyrate and from patients with urea cycle disorders, haemoglobinopathies and cirrhosis receiving single and repeated oral doses up to 20 g/day (uncontrolled studies). 
Plazemske in urinske koncentracije fenilbutirata ter njegovih presnovkov so bile določene pri teščih normalnih odraslih osebah, ki so prejele enkraten odmerek 5 g natrijevega fenilbutirata, in pri bolnikih z motnjami v ciklusu sečnine, hemoglobinopatijami ter cirozo, ki so prejeli enkraten odmerek ali ponavljajoče peroralne odmerke do 20 g/dan (nekontrolirane študije).
Common: Decreased blood potassium, albumin, total protein and phosphate. 
Pogosti: zmanjšana koncentracija kalija, albumina, celokupnih beljakovin in fosfata v krvi.
AMMONAPS granules should be administered orally (to infants and children unable to swallow tablets and to patients with dysphagia) or via gastrostomy or nasogastric tube. 
Zdravilo AMMONAPS zrnca se dajejo peroralno (dojenčkom in otrokom, ki ne morejo pogoltniti tablet, in bolnikom z disfagijo) ali preko gastrostome ali nazogastrične cevke.
In the majority of patients with urea cycle disorders or haemoglobinopathies receiving various doses of phenylbutyrate (300 - 650 mg/kg/day up to 20 g/day) no plasma level of phenylacetate could be detected after overnight fasting. 
Pri večini bolnikov z motnjami ciklusa sečnine ali hemoglobinopatijami, ki so prejemali različne odmerke fenilbutirata (300 - 650 mg/kg/dan do 20 g/dan) ni bilo moč zaznati plazemskih koncentracij fenilacetata po prekonočnem postu.
How to store AMMONAPS Contents of the pack and other information 
Shranjevanje zdravila AMMONAPS Vsebina pakiranja in dodatne informacije
Common: Depression, irritability 
Pogosti: depresija, preobčutljivost Bolezni živčevja
The frequency of possible side effects is listed below. 
Pogostnost spodaj naštetih možnih neželenih učinkov je opredeljena po naslednjem dogovoru:
If you are a woman who could get pregnant, you must use reliable contraception, during treatment with AMMONAPS. 
Če lahko zanosite, morate med jemanjem zdravila AMMONAPS uporabljati zanesljivo metodo kontracepcije.
This may be due to the lipophilicity of sodium phenylbutyrate and consequent differences in volume of distribution. 
Pojav najbrž lahko pripišemo lipofilnosti natrijevega fenilbutirata in posledičnih razlik v volumnu porazdelitve.